We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Treatment of granuloma annulare with tofacitinib.
- Authors
Bosch‐Amate, Xavier; Serra‐García, Laura; Alamon‐Reig, Francesc; Marti‐Marti, Ignasi; Gil‐Lianes, Javier; Giavedoni, Priscila; Mascaró, José M.
- Abstract
Granuloma annulare (GA) is a granulomatous, idiopathic, inflammatory skin disorder characterized by the formation of papules and plaques with annular and acral distribution.1 GA is often limited and self-resolving, but in some cases, it can be generalized and refractory to treatments.1 New advances in the pathophysiology of GA have favoured Janus kinase (JAK) inhibitors as a promising therapeutic option.1,2 Here, we report three cases of resistant generalized GA successfully treated with tofacitinib. Further studies are necessary to assess the safety and the long-term remission of GA patients treated with tofacitinib, and to study the efficacy of other JAK inhibitors in these patients. In addition, other JAK inhibitors such as baricitinib and upadacitinib have recently been used in two generalized GA patients with good results.7,8 In conclusion, advances in GA pathophysiology have allowed the introduction of JAK inhibitors as a new treatment option.
- Subjects
GRANULOMA
- Publication
Australasian Journal of Dermatology, 2022, Vol 63, Issue 3, p400
- ISSN
0004-8380
- Publication type
Article
- DOI
10.1111/ajd.13875